Featured
Search Clinical Trials
Active, Not Recruiting
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) (External Link)
Standard cytotoxic chemotherapy is based on the Medical Research Council (MRC) backbone of cytarabine, and daunorubicin. This combination of chemotherapy is highly myelosuppressive and can lead to oral aversions, dietary …
Baylor Role:
Lead Sponsor
Completed
High-Risk Neuroblastoma Chemotherapy Without G-CSF (External Link)
Chemotherapy: CYCLE 1+2: Topotecan and cyclophosphamide Cycle 3+5: Cisplatin and Etoposide Cycle 4+6: Vincristine, Cyclophosphamide and Doxorubicin Stem cell collection: After the third cycle of chemotherapy, stem cells will be …
Baylor Role:
Lead Sponsor
Completed
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (External Link)
The subject will need to have a variety of tests, exams, or procedures to find out if s/he can be on the study. The subject will also require placement of …
Baylor Role:
Lead Sponsor
Completed
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A (External Link)
At first the subject will have 2 cycles of cancer drugs (Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide). The doctors call this combination of cancer drugs ABVE-PC for short. A cycle …
Baylor Role:
Lead Sponsor
Completed
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma (External Link)
Induction Phase Overview The induction phase is approximately 15 weeks long. Chemotherapy is generally given every 3 weeks, each 3 week block is called a "cycle". During these 15 weeks …
Baylor Role:
Lead Sponsor
Completed
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients (External Link)
Large clinical trials have confirmed the value of systemic adjuvant therapy in decreasing the risk of recurrence and death in patients with early breast cancer. However, the need to identify …
Baylor Role:
Collaborator
Completed
Biologic Correlative Taxotere/AC (External Link)
Breast cancer and systemic chemotherapy: Systemic chemotherapy for operable breast cancer significantly decreases the risk of relapse and death. However, it is not possible to identify those patients at the …
Baylor Role:
Collaborator